Printed from https://fyi.org.nz./request/16571-ivermectin-as-a-covid-19-treatment-including-up-to-date-data-analysis-and-conversations on December 19, 2024 00:53

Ivermectin as a Covid 19 treatment - including up to date data analysis and conversations

Micky Turner made this Official Information request to Ministry of Health

The request was successful.

From: Micky Turner

Dear Ministry of Health,

This meta analysis of 66 studies which was just released within the past few days - indicates Ivermectin is likely highly effective in treating Covid 19:
https://ivmmeta.com/ (44 were peer reviewed)

It shows Ivermectin improved outcomes by:
86% if used as a preventative
72% if used early during infection
40% if used late during infection

Can you please forward the following information:

All documents the Ministry of Health has on Ivermectin as a Covid 19 treatment - including up to date data analysis and conversations.

Yours faithfully,

Micky Turner

Link to this

From: OIA Requests

Attachment image.png
6K Download

Kia ora Mickey
Thank you for your emails regarding ivermectin:
"1. How many doses of Ivermectin the Ministry of Health currently has
2. How many doses of Ivermectin the Ministry of Health has on order
3. If the Ministry of Health plans to add Ivermectin to their Covid 19
treatment & prevention protocols 

All documents the Ministry of Health has on Ivermectin as a Covid 19
treatment - including up to date data analysis and conversations."

Your request is refused under section 18(g)(i) of the Official Information
Act (the Act) as the information requested is not held by the Ministry and
there are no grounds for believing it is held by another agency subject to
the Act.

For Ivermectin to be approved for the prevention or treatment of COVID-19,
New Zealand legislation requires that a sponsor submits a medicine
application with appropriate safety and efficacy data to Medsafe, for
evaluation and approval before it can be supplied here. To date this has
not occurred. For information on who can be a medicine sponsor in New
Zealand (and therefore submit an application to Medsafe), you may wish to
refer to the Guidelines on the Regulation of Therapeutic Products in New
Zealand, Part 2, Section 2, available on Medsafe's
website: [1]https://www.medsafe.govt.nz/regulatory/c...

There is currently one medicine containing ivermectin approved for use in
New Zealand. The medicine is called Stromectol, and it is approved for a
number of clinical indications. However, these indications do not include
the treatment of COVID-19. More information about Stromectol including the
expected side effects of use, and the company that is registered as its
sponsor can be found in the New Zealand data
sheet here: [2]https://www.medsafe.govt.nz/profs/Datash...

More information on the regulation of medicines for the treatment of
COVID-19 can be found on our website
at: [3]https://www.medsafe.govt.nz/COVID-19/med...

Under section 28(3) of the Act you have the right to ask the Ombudsman to
review any decisions made under this request. The Ombudsman may be
contacted by email at: [email address] or by calling 0800 802
602.
Ngā mihi
 
Nick Allan
Manager, OIA Services
Office of the Director-General
Ministry of Health
E: [email address]

--------------------------------------------------------------------------

From: Micky Turner <[FOI #16571 email]>
Sent: Monday, 30 August 2021 12:36
To: OIA Requests <[email address]>
Subject: Official Information request - Ivermectin as a Covid 19 treatment
- including up to date data analysis and conversations
 
Dear Ministry of Health,

This meta analysis of 66 studies which was just released within the past
few days - indicates Ivermectin is likely highly effective in treating
Covid 19:
[4]https://scanmail.trustwave.com/?c=15517&...
(44 were peer reviewed)

It shows Ivermectin improved outcomes by:
86% if used as a preventative
72% if used early during infection
40% if used late during infection

Can you please forward the following information:

All documents the Ministry of Health has on Ivermectin as a Covid 19
treatment - including up to date data analysis and conversations.

Yours faithfully,

Micky Turner

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #16571 email]

Is [Ministry of Health request email] the wrong address for Official Information requests
to Ministry of Health? If so, please contact us using this form:
[5]https://scanmail.trustwave.com/?c=15517&...

Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[6]https://scanmail.trustwave.com/?c=15517&...

If you find this service useful as an Official Information officer, please
ask your web manager to link to us from your organisation's OIA or LGOIMA
page.

show quoted sections

This e-mail message has been scanned for Viruses and Content and cleared
by the Ministry of Health's Content and Virus Filtering Gateway

--------------------------------------------------------------------------

References

Visible links
1. https://www.medsafe.govt.nz/regulatory/c...
2. https://www.medsafe.govt.nz/profs/Datash...
3. https://www.medsafe.govt.nz/COVID-19/med...
4. https://scanmail.trustwave.com/?c=15517&...
5. https://scanmail.trustwave.com/?c=15517&...
6. https://scanmail.trustwave.com/?c=15517&...

Link to this

From: Micky Turner

Thanks Nicks,

So essentially anyone can import it and apply for Medsafe approval as either a prescription or over the counter product.

This is the link:
https://www.medsafe.govt.nz/regulatory/G...

Below are the details from Part 2, Section 2.

Thanks for your fast reply.

Cheers - Micky

Section 2: Who can submit an application
The Medicines Act 1981 requires that a New Medicine Application (NMA), New Related
Product Application (NRPA), Changed Medicine Application (CMN) or Changed
Related Product Notification (CRPN) is lodged by or in the name of a manufacturer,
importer or proprietor resident in New Zealand.
The New Zealand resident manufacturer, importer or proprietor may be an individual or a
company and is designated the “sponsor” (or “licence holder”) for the product concerned.
The sponsor is legally responsible for all aspects of the product in New Zealand, including
any regulatory action relating to it. The sponsor is responsible for ensuring the accuracy of
any information submitted to Medsafe in support of any NMA, NRPA, CMN or CRPN.
An overseas pharmaceutical company wishing to market a medicine or related product in
New Zealand therefore needs to have a New Zealand-based subsidiary, or appoint a local
individual or company as a New Zealand agent to act for them in New Zealand as sponsor
for the product concerned. The New Zealand subsidiary or agent is the sponsor responsible
for the product, including any supply of the product under section 2 of the Medicines Act and
any recall of the product from the market.

Link to this

Things to do with this request

Anyone:
Ministry of Health only: